Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

204.46 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories Intl

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
From Charles River Laboratories International, Inc.
Via Business Wire
This Favorable Sign Appears On Charles River's Chart
Via Benzinga
Why Charles River Laboratories Stock Is Jumping Today
Investors liked the company's Q3 update. 
Via The Motley Fool
Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Jim Cramer Says This Stock Is Undervalued: 'I Think That It's Coming Back'
On CNBC’s "Mad Money Lightning Round," Jim Cramer he wants to own Sherwin-Williams Co (NYSE: SHW). "Everything that they could possibly say negative about it is out there. 
Via Benzinga
Charles River Laboratories Acquires SAMDI Tech
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories, AbbVie, Star Bulk Carriers And This Big Bank Are CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said Charles River Laboratories International, Inc. (NYSE: CRL) is trading at 20 time 
Via Benzinga
Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches CliniPrime Suite of GMP-Compliant Cellular Products
From Charles River Laboratories International, Inc.
Via Business Wire
What Does Charles River's Debt Look Like?
Over the past three months, shares of Charles River Inc. (NYSE:CRL) increased by 16.70%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its... 
Via Benzinga
Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA Programs
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Opens Contract Vivarium Space in Chicago, Enhancing Access to AAALAC-Accredited, Turnkey Research Program
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at November Investor Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Demonstrates Excellence in Advanced Modalities at Neuroscience 2022
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Announces Cell Therapy Manufacturing Capacity Expansion, Reinforcing Commitment to CDMO Clients
From Charles River Laboratories International, Inc.
Via Business Wire
Analyst Ratings for Charles River
Over the past 3 months, 5 analysts have published their opinion on Charles River (NYSE:CRL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
United Therapeutics, Super Micro Computer, Novo Nordisk And Other Big Gainers From Wednesday
U.S. stocks closed lower on Wednesday, with the Dow Jones dropping more than 500 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Charles River: Q3 Earnings Insights
Charles River (NYSE:CRL) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Charles River beat estimated... 
Via Benzinga
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results. 
Via Benzinga
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session
Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results. 
Via Benzinga
Charles River Laboratories Announces Third-Quarter 2022 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Medpace Earnings Are 'Almost Unbelievable'; MEDP Stock Flies
Medpace earnings soared in Q3 as weakness in contract awards turned to strength, sending MEDP stock surging. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.